Want to join the conversation?
$AMGN said it plans to submit data from Phase 3 endeavor trial for potential authorization of the Kyprolis drug in combination with dexamethasone in the EU. This data serves as basis of supplemental NDA of Kyprolis in combination with dexamethasone for patients with relapsed multiple myeloma, which has been accepted for priority review by US FDA.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?